Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Therapeutic management of gliosarcoma in the stupp protocol and temozolomide era

View through CrossRef
Background: The clinical management of primary gliosarcoma grade IV with curative intent is not entirely defined and the available data are limited, so the therapeutic management may be a challenge The application of the Stupp protocol may be the only effective treatment option. Case report: We report the case of a 57-year-old woman with a gliosarcoma of the left frontal lobe treated in a curative intent. She underwent craniotomy, followed by adjuvant radioterapy and 6 cycles of temozolomide, according to the Stupp protocol, resulting in complete response after 3.5 years from diagnosis. Conclusions: Gliosarcoma and glioblastoma are different histopathological entities and the use of the Stupp protocol, specifically studied for glioblastoma, is an off label application of the treatment protocol. Efforts should be focused in order to assess the efficacy of this treatment modality and then on the prognosis carried by gliosarcoma tumor type.
Title: Therapeutic management of gliosarcoma in the stupp protocol and temozolomide era
Description:
Background: The clinical management of primary gliosarcoma grade IV with curative intent is not entirely defined and the available data are limited, so the therapeutic management may be a challenge The application of the Stupp protocol may be the only effective treatment option.
Case report: We report the case of a 57-year-old woman with a gliosarcoma of the left frontal lobe treated in a curative intent.
She underwent craniotomy, followed by adjuvant radioterapy and 6 cycles of temozolomide, according to the Stupp protocol, resulting in complete response after 3.
5 years from diagnosis.
Conclusions: Gliosarcoma and glioblastoma are different histopathological entities and the use of the Stupp protocol, specifically studied for glioblastoma, is an off label application of the treatment protocol.
Efforts should be focused in order to assess the efficacy of this treatment modality and then on the prognosis carried by gliosarcoma tumor type.

Related Results

Clinical Insights and Management Strategies for Gliosarcoma: A Case Report
Clinical Insights and Management Strategies for Gliosarcoma: A Case Report
Abstract Introduction: Gliosarcoma (GSM) is a rare, aggressive primary CNS tumor and a histopathological variant of glioblastoma, characterized by both glial and sarcomatou...
Gliosarcomas: A Rare Case Report at Viet Duc University Hospital and Review of the Literature
Gliosarcomas: A Rare Case Report at Viet Duc University Hospital and Review of the Literature
Gliosarcoma is a rare biphasic subtype of glioblastoma with the poor prognosis, principally affects adults; males are more frequently affected, with a male-to-female ratio of 1.8/1...
Fulvestrant Enhances Temozolomide Effectiveness Against Glioblastoma: Insights from a Preclinical Study
Fulvestrant Enhances Temozolomide Effectiveness Against Glioblastoma: Insights from a Preclinical Study
Introduction: Glioblastomas (GBM) are among the most aggressive primary brain tumors, as they are characterized by a median survival of less than 15 months. The...
EXTH-23. COMBINED EFFECTS OF NICLOSAMIDE AND TEMOZOLOMIDE AGAINST HUMAN GLIOBLASTOMA TUMORSPHERES
EXTH-23. COMBINED EFFECTS OF NICLOSAMIDE AND TEMOZOLOMIDE AGAINST HUMAN GLIOBLASTOMA TUMORSPHERES
Abstract PURPOSE Glioblastoma (GBM) is the most aggressive type of brain tumor and has poor survival outcomes, even after a comb...
Synthesis, Characterization and Evaluation of Cadmium Sulfide Nanoparticles Capped with Dextrin and Functionalized with Temozolomide
Synthesis, Characterization and Evaluation of Cadmium Sulfide Nanoparticles Capped with Dextrin and Functionalized with Temozolomide
Nanoparticles are currently used as drug carriers. Temozolomide is an antineoplastic drug for tumor in central nervous system. It presents a half‐life of 1.8 hours. For this reason...
Detailed magnetic resonance imaging features of a case series of primary gliosarcoma
Detailed magnetic resonance imaging features of a case series of primary gliosarcoma
Objective We aimed to characterise the magnetic resonance imaging (MRI) features of a case series of primary gliosarcoma, with the inclusion of diffusion-weight...
Gliosarcoma in a Paediatric Patient: A Rare Entity and Review of Literature
Gliosarcoma in a Paediatric Patient: A Rare Entity and Review of Literature
Primary Gliosarcoma is a rare malignant tumour of central nervous system in adults. It is usually a variant of Isocitrate Dehydrogenase (IDH) wild type glioblastoma. Its incidence ...
HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy
HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy
Pituitary adenomas usually develop temozolomide resistance, which could compromise the anticancer effects of temozolomide. Suppression of hypoxia-inducible factor 1α has been shown...

Back to Top